| Name | Title | Contact Details |
|---|---|---|
Frederic Dross |
Vice President of Technology Americas | Profile |
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company`s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia`s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.
Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.
Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology.
Quadrant Laboratories is a subsidiary of Quadrant Biosciences, a life sciences company focused on improving the lives of children and families through innovative diagnostic, therapeutic, and virtual care solutions for global health priorities. Quadrant...